crysvita 10 mg
medison pharma ltd - burosumab - solution for injection - burosumab 10 mg / 1 ml - burosumab - crysvita is indicated for the treatment of x-linked hypophosphatemia (xlh) in adult and paediatric patients 6 months of age and oldertumor-induced osteomalaciacrysvita is indicated for the treatment of fgf23‐related hypophosphatemia in tumor‐induced osteomalacia (tio) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.
crysvita 20 mg
medison pharma ltd - burosumab - solution for injection - burosumab 20 mg / 1 ml - burosumab - crysvita is indicated for the treatment of x-linked hypophosphatemia (xlh) in adult and paediatric patients 6 months of age and oldertumor-induced osteomalaciacrysvita is indicated for the treatment of fgf23‐related hypophosphatemia in tumor‐induced osteomalacia (tio) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.
crysvita 30 mg
medison pharma ltd - burosumab - solution for injection - burosumab 30 mg / 1 ml - burosumab - crysvita is indicated for the treatment of x-linked hypophosphatemia (xlh) in adult and paediatric patients 6 months of age and oldertumor-induced osteomalaciacrysvita is indicated for the treatment of fgf23‐related hypophosphatemia in tumor‐induced osteomalacia (tio) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.
cystadrops 3.8 mgml
medison pharma ltd - mercaptamine as hydrochloride - ophthalmic solution - mercaptamine as hydrochloride 3.8 mg - mercaptamine - cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.
cystadrops 3.8 mgml
medison pharma ltd - mercaptamine as hydrochloride - ophthalmic solution - mercaptamine as hydrochloride 3.8 mg - mercaptamine - cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.
xadago 100 mg
medison pharma ltd - safinamide as methanesulfonate - film coated tablets - safinamide as methanesulfonate 100 mg - safinamide - xadago is indicated for the treatment of adult patients with idiopathic parkinson’s disease (pd) as add-on therapy to a stable dose of levodopa (l-dopa) alone or in combination with other pd medicinal products in mid-to late-stage fluctuating patients.
xadago 50 mg
medison pharma ltd - safinamide as methanesulfonate - film coated tablets - safinamide as methanesulfonate 50 mg - safinamide - xadago is indicated for the treatment of adult patients with idiopathic parkinson’s disease (pd) as add-on therapy to a stable dose of levodopa (l-dopa) alone or in combination with other pd medicinal products in mid-to late-stage fluctuating patients.
brukinsa
medison pharma ltd - zanubrutinib - capsules - zanubrutinib 80 mg - • brukinsa is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.• brukinsa is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm).• brukinsa is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (mzl) who have received at least one anti-cd20-based regimen.• brukinsa is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll).
tavalisse 100 mg
medison pharma ltd - fostamatinib as disodium hexahydrate - film coated tablets - fostamatinib as disodium hexahydrate 100 mg - fostamatinib - tavalisse is indicated for the treatment of chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments.
tavalisse 150 mg
medison pharma ltd - fostamatinib as disodium hexahydrate - film coated tablets - fostamatinib as disodium hexahydrate 150 mg - fostamatinib - tavalisse is indicated for the treatment of chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments.